PDCD1 and cancer: Thus, our discovery of sClever-1 associated with extracellular vesicles in human serum, its positive correlation with cancer and negative correlation with anti-PD-1 response, and its reduced levels after bexmarilimab treatment provide a promising platform to explore the potential of sClever-1 as a cancer prognostic and therapeutic biomarker.